Table 2.
Treating Physicians Importance Ratings (0-5) for Initiation of ADT for BCR
| Variable | Mean Importance Rating Scores (0-5) by Physician Type |
||
|---|---|---|---|
| Attending (n = 7) | Fellow (n = 13) | Total (N = 20) | |
| PSA doubling time* | 4.7 | 4.8 | 4.8 |
| Patient preference | 4.6 | 4.4 | 4.5 |
| Time from primary treatment to PSA increase* | 4.4 | 3.9 | 4.1 |
| PSA level | 4.1 | 4.0 | 4.1 |
| Patient remaining life expectancy | 4.0 | 4.0 | 4.0 |
| Gleason grade* | 4.1 | 3.8 | 3.9 |
| Efficacy of treatment | 3.7 | 4.0 | 3.9 |
| Adverse effects of treatment | 4.0 | 3.8 | 3.9 |
| Stage at diagnosis | 3.9 | 3.8 | 3.8 |
| Geriatric comorbidities† | 3.7 | 3.7 | 3.7 |
| Previous treatment history | 3.3 | 3.9 | 3.7 |
| Medical comorbidities‡ | 3.6 | 3.5 | 3.5 |
| Partner preferences | 3.9 | 3.8 | 3.4 |
| Level of patient anxiety about cancer | 3.6 | 3.3 | 3.4 |
| PSA at diagnosis | 3.3 | 3.3 | 3.3 |
| Treatment cost | 2.4 | 2.6 | 2.6 |
Abbreviations: ADT, androgen deprivation therapy; BCR, biochemical cancer recurrence; PSA, prostate-specific antigen.
*
Factors found important in the literature for predicting response to ADT.
†
Examples of geriatric comorbidities include cognitive impairment, functional losses, osteoporosis.
‡
Examples of medical comorbidities include cardiovascular disease, diabetes, chronic renal insufficiency.